Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from RenovoRx ( (RNXT) ).
RenovoRx reported its full-year 2025 results on March 30, 2026, highlighting $1.1 million in RenovoCath revenue in its first full year of commercialization and growing adoption at 12 U.S. cancer centers, with 21 more in the pipeline. The company completed the initial buildout of its commercial infrastructure, expanded its sales and marketing capabilities, and strengthened its balance sheet with a recent $10 million private placement, leaving $13 million in cash to support its growth strategy and operational milestones.
The company’s pivotal Phase III TIGeR-PaC trial in locally advanced pancreatic cancer advanced during 2025, passing its second interim analysis with a recommendation to continue and reaching 104 randomized patients and 72 events as of March 24, 2026. RenovoRx expects to complete trial enrollment by mid-2026, is planning to convert 17 TIGeR-PaC centers to commercial RenovoCath customers, and is broadening its clinical footprint through registry and investigator-initiated studies, supported by a new CFO appointment and a medical advisory board formed in February 2026.
The most recent analyst rating on (RNXT) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on RenovoRx stock, see the RNXT Stock Forecast page.
Spark’s Take on RNXT Stock
According to Spark, TipRanks’ AI Analyst, RNXT is a Neutral.
The score is held back primarily by weak financial performance—large operating losses and substantial cash burn despite improving revenue and a low-debt balance sheet. Technicals are comparatively supportive with the stock above major moving averages and positive MACD, while valuation is constrained by negative earnings. The latest earnings call was broadly positive on commercial expansion and trial progress, but this is partially offset by the Nasdaq bid-price compliance risk.
To see Spark’s full report on RNXT stock, click here.
More about RenovoRx
RenovoRx, Inc., based in Mountain View, Calif., is a life-sciences company focused on targeted oncology therapies and the commercialization of RenovoCath, a patented, FDA-cleared intra-arterial drug-delivery device. The company targets high-volume U.S. cancer centers and is building its TAMP therapy platform for treatment of solid tumors, including locally advanced pancreatic cancer.
Average Trading Volume: 336,161
Technical Sentiment Signal: Buy
Current Market Cap: $41.41M
See more insights into RNXT stock on TipRanks’ Stock Analysis page.